Privium Fund Management B.V. Boosts Stake in Arrowhead Pharmaceuticals, to Drive Growth
☀️Trending News The move by Privium Fund Management B.V. is seen as a vote of confidence in the company and [...]
Arrowhead Pharmaceuticals Intrinsic Value – Arrowhead Pharmaceuticals Announces Inducement Grants for New Employees in Compliance with NASDAQ Listing Rule
☀️Trending News Arrowhead Pharmaceuticals ($NASDAQ:ARWR), Inc. is a biopharmaceutical company that focuses on the development and commercialization of RNA interference [...]
Arrowhead Pharmaceuticals Intrinsic Value Calculator – Arrowhead’s Plozasiran Shows Promising Phase 3 Data for FCS, But Investment Opportunity Remains Uncertain
☀️Trending News Arrowhead Pharmaceuticals ($NASDAQ:ARWR) is a biotechnology company that focuses on developing innovative RNA interference (RNAi) therapies for various [...]
ARROWHEAD PHARMACEUTICALS Prices $450M Common Stock Offering
🌥️Trending News Arrowhead Pharmaceuticals ($NASDAQ:ARWR), a biopharmaceutical company based in Pasadena, California, has priced a common stock offering in the [...]
ARROWHEAD PHARMACEUTICALS Reports Earnings Miss, Revenue Miss for Q4
🌧️Trending News Unfortunately, their results were worse than what analysts had expected. Their GAAP earnings per share (EPS) of -$1.92 [...]
Invest in Arrowhead Pharmaceuticals for a Risky but Potentially Rewarding Opportunity
☀️Trending News Arrowhead Pharmaceuticals ($NASDAQ:ARWR) is a California-based biopharmaceutical company that is focused on discovering, developing, and commercializing innovative therapies [...]
ARROWHEAD PHARMACEUTICALS Reports FY2023 Q3 Earnings Results for June 30 2023
🌥️Earnings Overview On August 7 2023, ARROWHEAD PHARMACEUTICALS ($NASDAQ:ARWR) reported their Fiscal Year 2023 Third Quarter earnings results as of [...]
ARROWHEAD PHARMACEUTICALS Reports 51.2% Decrease in Total Revenue for Third Quarter of FY2023
🌥️Earnings Overview ARROWHEAD PHARMACEUTICALS ($NASDAQ:ARWR) announced their earnings results for the third quarter of FY2023 on August 7 2023, with [...]
ARROWHEAD PHARMACEUTICALS Reports 51.2% Decrease in Total Revenue for Third Quarter of FY 2023
🌥️Earnings Overview For the third quarter of Fiscal Year 2023, ending June 30 2023, ARROWHEAD PHARMACEUTICALS ($NASDAQ:ARWR) reported total revenue [...]
Arrowhead Pharmaceuticals Anticipates Exciting Q3 Earnings Results Amid Positive Sentiments
☀️Introduction: Arrowhead Pharmaceuticals is poised to release its highly anticipated Q3 earnings results on August 7th, 2023, at 4:30 PM [...]
